New valve offers hope for High-Risk heart patients
NCT ID NCT07334691
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new device called the Cardiovalve system to treat severe tricuspid regurgitation, a condition where a heart valve leaks. About 150 people aged 18-84 who are too high-risk for open-heart surgery will receive the valve. The goal is to see if the valve safely reduces leakage and improves daily function and quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRICUSPID REGURGITATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Uniklinik Bonn -
RECRUITINGBonn, 53127, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new Catheter-Based valve could fix a leaky heart valve without surgery
- New clip device aims to repair leaky heart valve without Open-Heart surgery
- New study aims to simplify care for patients with multiple leaky heart valves
- 5,500 patients to test new heart valve devices in massive safety study
- Heart valve repair devices under 5-Year safety spotlight
- Study aims to find best treatment for leaky heart valve in older adults